{"id":7415,"date":"2023-03-21T12:47:14","date_gmt":"2023-03-21T12:47:14","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7415"},"modified":"2023-03-21T12:47:14","modified_gmt":"2023-03-21T12:47:14","slug":"research-group-on-translational-genomics","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/que-hacemos\/areas\/metabolismo-y-dano-organico\/research-group-on-translational-genomics\/","title":{"rendered":"Research Group on Translational Genomics"},"content":{"rendered":"

\n
\n

Research Group on Translational Genomics<\/h3>\n<\/div>\n
<\/div><\/div>\n
Metabolism and Organic Damage Area<\/span><\/h5>\n<\/div>\n
<\/div><\/div>\n
\n
\n During 2021 the group has accomplished the publishing of scientific studies based on the main research strategy of looking for new drug candidates for neuromuscular (DM and SMA) rare diseases, but also on more prevalent diseases as those related with kidney pathologies. At the same time, it has been established a solid relationship with the spin-off Arhtex Biotech S.L. on the basis of several research contracts, on its goal of developing promising molecules with therapeutic potential in DM. The group has been awarded with Prometeo funds as “Excellent Research group” involving researchers also from Biodonostia, Biosensors_IBEC and IQAC-CSIC. Also significant, our PhD student, Sarah Overby, was one of the recipients for the renowned Grants from Myotonic Foundation.
\n\n<\/div>\n<\/div>\n<\/div><\/div>